In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amylin, Alkermes develop long-acting diabetes drug

Executive Summary

In a deal that will enable Amylin Pharmaceuticals to develop a once-a-month, Type II diabetes treatment based on its synthetic exendin-4 (AC2993), the company licensed exclusive worldwide rights to Alkermes Pharmaceuticals' Medisorb injectable, sustained-release drug delivery technology.
Deal Industry
  • Biotechnology
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register